Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by FredTheVoiceon Aug 12, 2019 9:22am
167 Views
Post# 30017389

Press release

Press releaseHere is the official press release this morning. I think ist pretty normal that the Chief financial officer informs investors for that kind of news. GOOD NEWS !!! Good timing as well. Fall should be interesting !

THERATECHNOLOGIES FILES APPLICATION TO LIST ON NASDAQ

Montreal, Canada – August 12, 2019 – Theratechnologies Inc. (“Theratechnologies”or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ.

“We believe that being listed on NASDAQ will help to foster interest from more potential investors and financial analysts, and that it should result in increased liquidity for investors. Theratechnologies will enter NASDAQ with a strong commercial portfolio and a research pipeline that will undoubtedly attract more attention and be betterrecognized,” said Philippe Dubuc, Senior Vice-President and Chief Financial Officer, Theratechnologies Inc.

In connection with its application to list on NASDAQ, Theratechnologies will file a Form 40-F Registration Statement with the United States Securities and Exchange Commission. The listing of the Company’s common shares on NASDAQ remains subject to the approval of NASDAQ and the satisfaction of all applicable listing and regulatory requirements. Based on its typical review process, it is expected that theCompany’s common shares will be listed on NASDAQ within the next 60 days.

The Company will maintain its common share listing on the Toronto Stock Exchange under the symbol “TH”.

FTV.


Bullboard Posts